ReviewLife (Basel, Switzerland)2024
Medication-Overuse Headache: Update on Management.
Review in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07568496 (Greater Occipital Nerve Block for Migraine With Medication Overuse Headache), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Greater Occipital Nerve Block for Migraine With Medication Overuse Headache
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of Educational and Behavioral Interventions on Medication-Overuse Headache: A Systematic Review and Meta-Analysis.Pain research & management · 2026Pooled it
- Network meta-analysis comparing efficacy of different strategies on medication-overuse headache.The journal of headache and pain · 2025Pooled it
- Article
- Chronic Migraine Resistance: A Case Report Highlights an Overlooked Factors in Family Medicine Clinics.Healthcare (Basel, Switzerland) · 2026Article
- The relationship between triglyceride levels and medication overuse headache in patients with chronic migraine.Journal of oral & facial pain and headache · 2026Article
- Electroacupuncture alleviates migraine through CXCL13/CXCR5-mediated communication.Chinese medicine · 2026Article
- Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States.Frontiers in neurology · 2026Observational
- Pharmacovigilance Insights into Ibuprofen's Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sishun Formula for acute migraine attack: study protocol for a double-blind, randomized, placebo-controlled trial.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term frequent use of acute pain medication for the treatment of headaches has paradoxically been shown to increase the frequency of headaches. So-called medication-overuse headache (MOH) is particularly problematic in patients with migraine who overuse triptans and opioids. Prevention through education remains the most important management strategy. Once established, MOH can be difficult to treat. Although complete or near-complete withdrawal of acute pain medication for 8-12 weeks has been shown to benefit most patients, this can be hard to achieve. The use of OnabotulinumtoxinA and drugs that target the calcitonin gene-related peptide system for the prevention of migraines have been shown to benefit patients with MOH. Furthermore, the use of novel acute pain medication for migraines, including Gepants and Ditans, which do not cause MOH, are likely to improve patient outcomes. In this review article we examine the following: the burden of MOH; who develops MOH; the pathophysiological mechanisms; and the treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.